Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment.

Genes - 13 Apr 2022

Secondino Angela, Starnone Flavio, Veneruso Iolanda, Di Tella Maria Antonietta, Conato Serena, De Angelis Carmine, De Placido Sabino, D'Argenio Valeria

Abstract excerpt

BRCA1/2 are tumor suppressor genes involved in DNA double-strand break repair. They are the most penetrant genes for hereditary breast and ovarian cancers, but pathogenic variants in these two genes can be identified only in a fraction of hereditary cases. Following the diffusion of BRCA molecular testing and the availability of specific therapeutic strategies for the management of pathogenic variant carriers,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, BRCA2
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Ovarian Neoplasms

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 35456488
DOI: 10.3390/genes13040682
PMCID: PMC9024623

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment.PMID 35456488Read ↗

Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.Semantic proximity Read ↗

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?Semantic proximity Read ↗

Profiling of the genetic features of patients with breast, ovarian, colorectal and extracolonic cancers: Association to CHEK2 and PALB2 germline mutations.Semantic proximity Read ↗

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.Semantic proximity Read ↗

Variant reclassification in cancer susceptibility genes and an updated variant spectrum of Turkish breast and colorectal cancer patients.Semantic proximity Read ↗

Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.Semantic proximity Read ↗

Beyond BRCA: new hereditary breast cancer susceptibility genes.Semantic proximity Read ↗

A new paradigm of genetic testing for hereditary breast/ovarian cancers.Semantic proximity Read ↗

Mutational profile of hereditary breast and ovarian cancer - Establishing genetic testing guidelines in a developing country.Semantic proximity Read ↗

Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.Semantic proximity Read ↗

Multigene panel testing reveals the spectrum of non-BRCA germline variants in BRCA1/2-negative breast, ovarian, and prostate cancer patients from a Turkish cohort.Semantic proximity Read ↗

Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.